Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wakefield

Showing results (641-650 of 661) with videos related to

Pageof 67
Sort By:
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Cancer Research|October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with EribulinGwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 4, 2023
Targeting homologous recombination deficiency in uterine leiomyosarcomaGenevieve Dall, Cassandra J Vandenberg, Ksenija Nesic, et al.
Nature Communications|November 5, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trialChee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Rheumatology (Oxford, England)|April 30, 2019
Development of semiquantitative ultrasound scoring system to assess cartilage in rheumatoid arthritisPeter Mandl, Paul Studenic, Emilio Filippucci, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
The Journal of Rheumatology|March 17, 2012
Patient-reported outcomes in polymyalgia rheumaticaEric L Matteson, Hilal Maradit-Kremers, Marco A Cimmino, et al.
Pageof 67

Showing results (641-650 of 661) with videos related to

Sort By:
Pageof 67
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Cancer Research|October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with EribulinGwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 4, 2023
Targeting homologous recombination deficiency in uterine leiomyosarcomaGenevieve Dall, Cassandra J Vandenberg, Ksenija Nesic, et al.
Nature Communications|November 5, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trialChee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Rheumatology (Oxford, England)|April 30, 2019
Development of semiquantitative ultrasound scoring system to assess cartilage in rheumatoid arthritisPeter Mandl, Paul Studenic, Emilio Filippucci, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
The Journal of Rheumatology|March 17, 2012
Patient-reported outcomes in polymyalgia rheumaticaEric L Matteson, Hilal Maradit-Kremers, Marco A Cimmino, et al.
Pageof 67